Bhang Inc.

OTC: BHNGF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Toronto, ONReports USD

#841 of 1,394 Healthcare companies by revenue28th-percentile growth

EA Score

——

FH —DQ —GM —SS 41

v0.1 · 5/100 weight · pillars only

↑ listing tenure, Piotroski F · ↓ Altman-Z, market scale

Methodology →

Revenue TTM

$1.4M

Rev growth YoY (TTM)

+68.8%

Net income (FY)

-$3.4M

Employees

Market cap

$20.0k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.3M1.6M CAD2021

Net income-$3.4M-4.2M CAD2021

Operating income-$3.0M-3.7M CAD2021

Total assets$1.7M2.2M CAD2021

Liabilities$2.0M2.5M CAD2021

Equity-$258.9k-328.2k CAD2021

Revenue trend

FY2017 – FY2021 · USD

$1.9M

FY17

$1.7M

FY18

$4.6M

FY19

$1.5M

FY20

$1.3M

FY21

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Bhang Inc. booked $1.3M in FY2021 revenue, contracting 17% year over year — slower than 72% of Healthcare companies we track, at a -260.4% net margin.

Peers · Healthcare

PrimeMD Inc——CanaFarma Hemp Products Corp.——Scopus BioPharma Inc.——Encision Inc.——

Key facts

CEOJohn Graham Simmonds Jr.

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersToronto, ON

ExchangeOTC: BHNGF

Employees14

IPO date2007-05-16

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.